Aim immunotech inc.'s drug ampligen awarded fda's orphan drug designation status for the treatment of pancreatic cancer

Ocala, fla., dec. 21, 2020 (globe newswire) -- aim immunotech inc. (nyse american: aim), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the u.s. food and drug administration on december 17, 2020 granted orphan drug designation status to aim's drug ampligen (rintatolimod) for the treatment of pancreatic cancer.
AIM Ratings Summary
AIM Quant Ranking